134 related articles for article (PubMed ID: 12975594)
21. Mapping the dose-effect relationship of orbofiban from sparse data with an artificial neural network.
Mager DE; Shirey JD; Cox D; Fitzgerald DJ; Abernethy DR
J Pharm Sci; 2005 Nov; 94(11):2475-86. PubMed ID: 16200613
[TBL] [Abstract][Full Text] [Related]
22. Oral platelet glycoprotein IIb/IIIa inhibition.
Newby LK; McGuire DK
Curr Cardiol Rep; 2000 Sep; 2(5):372-7. PubMed ID: 10980903
[TBL] [Abstract][Full Text] [Related]
23. Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.
Wang X; Dorsam RT; Lauver A; Wang H; Barbera FA; Gibbs S; Varon D; Savion N; Friedman SM; Feuerstein GZ
J Pharmacol Exp Ther; 2002 Dec; 303(3):1114-20. PubMed ID: 12438534
[TBL] [Abstract][Full Text] [Related]
24. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.
Vorchheimer DA; Badimon JJ; Fuster V
JAMA; 1999 Apr; 281(15):1407-14. PubMed ID: 10217057
[TBL] [Abstract][Full Text] [Related]
25. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
Chakrabarti S; Clutton P; Varghese S; Cox D; Mascelli MA; Freedman JE
Thromb Res; 2004; 113(3-4):225-33. PubMed ID: 15140587
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial.
Kereiakes DJ; Kleiman NS; Ferguson JJ; Masud AR; Broderick TM; Abbottsmith CW; Runyon JP; Anderson LC; Anders RJ; Dreiling RJ; Hantsbarger GL; Bryzinski B; Topol EJ
Circulation; 1998 Sep; 98(13):1268-78. PubMed ID: 9751674
[TBL] [Abstract][Full Text] [Related]
27. Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology.
Brassard JA; Curtis BR; Cooper RA; Ferguson J; Komocsar W; Ehardt M; Kupfer S; Maurath C; Swabb E; Cannon CP; Aster RH
Thromb Haemost; 2002 Dec; 88(6):892-7. PubMed ID: 12529735
[TBL] [Abstract][Full Text] [Related]
28. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
Straub A; Wendel HP; Azevedo R; Ziemer G
Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
[TBL] [Abstract][Full Text] [Related]
29. Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development.
Verstraete M
Circulation; 2000 Feb; 101(6):E76-80. PubMed ID: 10673265
[TBL] [Abstract][Full Text] [Related]
30. Advancing the battle against acute ischemic syndromes: a focus on the GP IIb-IIIa inhibitors.
Dobesh PP; Latham KA
Pharmacotherapy; 1998; 18(4):663-85. PubMed ID: 9692642
[TBL] [Abstract][Full Text] [Related]
31. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.
Kereiakes DJ; Kleiman N; Ferguson JJ; Runyon JP; Broderick TM; Higby NA; Martin LH; Hantsbarger G; McDonald S; Anders RJ
Circulation; 1997 Aug; 96(4):1117-21. PubMed ID: 9286938
[TBL] [Abstract][Full Text] [Related]
32. Role of glycoprotein IIb-IIIa (alpha IIb beta 3-integrin) in stimulation of secretion from platelet granules.
Naimushin YA; Mazurov AV
Biochemistry (Mosc); 2003 Feb; 68(2):209-16. PubMed ID: 12693968
[TBL] [Abstract][Full Text] [Related]
33. Clinical pharmacology of eptifibatide.
Phillips DR; Scarborough RM
Am J Cardiol; 1997 Aug; 80(4A):11B-20B. PubMed ID: 9291241
[TBL] [Abstract][Full Text] [Related]
34. Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial.
Topol EJ; Easton JD; Amarenco P; Califf R; Harrington R; Graffagnino C; Davis S; Diener HC; Ferguson J; Fitzgerald D; Shuaib A; Koudstaal PJ; Theroux P; Van de Werf F; Willerson JT; Chan R; Samuels R; Ilson B; Granett J
Am Heart J; 2000 Jun; 139(6):927-33. PubMed ID: 10827369
[TBL] [Abstract][Full Text] [Related]
35. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
[TBL] [Abstract][Full Text] [Related]
36. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.
Cannon CP; McCabe CH; Borzak S; Henry TD; Tischler MD; Mueller HS; Feldman R; Palmeri ST; Ault K; Hamilton SA; Rothman JM; Novotny WF; Braunwald E
Circulation; 1998 Feb; 97(4):340-9. PubMed ID: 9468207
[TBL] [Abstract][Full Text] [Related]
37. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML;
Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255
[TBL] [Abstract][Full Text] [Related]
38. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction.
Ault KA; Cannon CP; Mitchell J; McCahan J; Tracy RP; Novotny WF; Reimann JD; Braunwald E
J Am Coll Cardiol; 1999 Mar; 33(3):634-9. PubMed ID: 10080462
[TBL] [Abstract][Full Text] [Related]
39. Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
Liu F; Craft RM; Morris SA; Carroll RC
Expert Opin Investig Drugs; 2000 Nov; 9(11):2673-87. PubMed ID: 11060829
[TBL] [Abstract][Full Text] [Related]
40. The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes.
Stringer KA
Ann Pharmacother; 1999 Jun; 33(6):712-22. PubMed ID: 10410186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
